We are live on
!
Find out more
Recursion Pharmaceuticals
RXRX
RXRX
334 hedge funds and large institutions have $1.03B invested in Recursion Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 132 increasing their positions, 81 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
64% more call options, than puts
Call options by funds: $17.9M | Put options by funds: $10.9M
63% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 81
28% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 47
1.37% more ownership
Funds ownership: 63.04% → 64.4% (+1.4%)
0% more funds holding
Funds holding: 333 → 334 (+1)
22% less capital invested
Capital invested by funds: $1.33B → $1.03B (-$294M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
334
Holders Change
+1
Holders Change %
+0.3%
% of All Funds
4.11%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
60
Increased
132
Reduced
81
Closed
47
Calls
$17.9M
Puts
$10.9M
Net Calls
+$6.98M
Net Calls Change
-$3.58M
Top Buyers
| 1 |
BlackRock
New York
|
+$16.7M |
| 2 |
Goldman Sachs
New York
|
+$14.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$12.2M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$11.2M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$10.2M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$13.9M |
| 2 |
Morgan Stanley
New York
|
-$13.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.68M |
| 4 |
Barclays
London,
United Kingdom
|
-$5.09M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$3.59M |
